| CASE REPORT |
|
| Year : 2021 | Volume
: 21
| Issue : 3 | Page : 144-147 |
|
|
Successful kidney transplantation of a patient with thalassemia major: case report and review of literature
Mohamed Emam1, Mohamed A Moneem1, Osama Gheith2, Tarek Mahmoud3, Ayman M Nagib3, Khalid Abdultawab1, Zakaria Elsayed1, Prasad Nair4, Torki Al-otaibi1
1 Department of Internal Medicine and Nephrology, Hamed Alessa Organ Transplant Center, Kuwait
2 Department of Internal Medicine and Nephrology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
3 MRCP-E Internal Medicine and Nephrology, Hamed Alessa Organ Transplant Center, Kuwait
4 MRCP-I Internal Medicine and Nephrology, Hamed Alessa Organ Transplant Center, Kuwait
Correspondence Address:
Dr. Osama Gheith
Internal Medicine and Nephrology, Consultant Nephrologist, Urology and Nephrology Center, Mansoura University; Working in Hamed Alessa Organ Transplant Center, Kuwait; Hamed Al-Essa Organ Transplant Center, Ministry of Health, Ibn Sina Hospital, P.O. Box 25427, Safat (13115), Kuwait
Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jesnt.jesnt_5_21
|
|
|
Thalassemia minor has a good prognosis, whereas thalassemia major (TM) is a severe disease, and the long-term prognosis depends on the treatment adherence to transfusion and iron chelation therapies. To our knowledge, there are no reported thalassemia cases that underwent kidney transplant. We aimed to highlight a successful kidney transplant in a patient with TM with stable graft function after 16 months of follow-up. In our case, repeated blood transfusions were inevitably associated with iron overload despite iron chelating agents. Moreover, she developed anti-HLA antibodies, but fortunately, there were no donor-specific antibodies, which facilitated the procedure of renal transplant that was performed on 17/3/2019. After 6 weeks of transplant, she started follow-up in the clinic and resumed iron chelation using deferasirox along with much less frequent blood transfusion. After more than 20 months of follow-up, she is enjoying stable graft function, hemoglobin around 9.2 g/dl, and with occasional trace proteinuria. This is a case report showing a β-TM case can undergo renal transplant with no contraindications under special circumstances, and it is the first case in the literature.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
![JOURNAL_FULL_NAME]](images/logo.gif){kind=logo}
Next article
